Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic insights into MTHFR and SLC19A1 variants in low-dose methotrexate therapy for rheumatologic diseases.

Drug metabolism and personalized therapy - 1 Dec 2025

Martínez Téllez Goitybell, Teruel Beatriz Marcheco

Abstract excerpt

The identification of genetic markers that will enable accurate diagnosis and prediction of the therapy outcome is a crucial step in managing rheumatologic and autoimmune diseases. Low-dose methotrexate is a mainstay therapeutic agent for treatment. The objective of this review is to summarize the data on candidate single nucleotide polymorphisms in methylenetetrahydrofolate reductase (MTHFR) and solute carrier...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antirheumatic Agents
Share to MTHFR gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Methotrexate

Share to Methylenetetrahydrofolate Reductase (NADPH2)

Share to Pharmacogenetics

Share to Polymorphism, Single Nucleotide

Share to Reduced Folate Carrier Protein

Share to Rheumatic Diseases

Source

Identifiers

PMID: 41259404
DOI: 10.1515/dmpt-2025-0047

Genes

MTHFR
SLC19A1

Variants

rs1801131
rs1801133
rs1051266

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic insights into MTHFR and SLC19A1 variants in low-dose methotrexate therapy for rheumatologic diseases.PMID 41259404Read ↗

Polymorphisms and Pharmacogenomics for the Clinical Efficacy of Methotrexate in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

The association between methotrexate metabolism-related gene polymorphisms and therapeutic efficacy and toxicity in patients with rheumatoid arthritis.Semantic proximity Read ↗

Polymorphisms in Methotrexate Pathways: What Is Clinically Relevant, What Is Not, and What Is PromisingSemantic proximity Read ↗

Effect of Genetic Polymorphisms in the Folate Pathway on Methotrexate Therapy in Rheumatic DiseasesSemantic proximity Read ↗

The impact of gene polymorphisms on the response of methotrexate-based treatments.Semantic proximity Read ↗

Factors Underlying Failure of Methotrexate Treatment in Rheumatoid Arthritis: Implications in Personalized CareSemantic proximity Read ↗

The pharmacogenetics of methotrexateSemantic proximity Read ↗

Methotrexate: Implications of pharmacogenetics in the treatment of patients with Rheumatoid Arthritis.Semantic proximity Read ↗

Pharmacogenetics of methotrexateSemantic proximity Read ↗

Methotrexate pharmacogenetics in rheumatoid arthritis: a status report.Semantic proximity Read ↗

MTHFR C677T polymorphism is associated with methotrexate-induced myelopathy risk.Semantic proximity Read ↗

Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.